Emerg Infect Dis. 2023 Apr;29(4):696-700. doi: 10.3201/eid2904.221439.
During the SARS-CoV-2 pandemic, few cases of Nocar-dia spp. co-infection have been reported during or after a COVID-19 infection. Nocardia spp. are gram-positive aerobic actinomycetes that stain partially acid-fast, can infect immunocompromised patients, and may cause dis-seminated disease. We report the case of a 52-year-old immunocompromised man who had Nocardia pseudobrasiliensis pneumonia develop after a SARS-CoV-2 in-fection. We also summarize the literature for no-cardiosis and SARS-CoV-2 co-infections. Nocardia spp. infection should remain a part of the differential diagnosis for pneumonia in immunocompromised hosts, regardless of other co-infections. Sulfonamide/carbapenem combina-tions are used as empiric therapy for nocardiosis; species identification and susceptibility testing are required to se-lect the optimal treatment for each patient.
在 SARS-CoV-2 大流行期间,在 COVID-19 感染期间或之后,很少有诺卡氏菌属合并感染的病例报告。诺卡氏菌属是革兰阳性需氧放线菌,部分抗酸染色阳性,可感染免疫功能低下的患者,并可能引起播散性疾病。我们报告了一例 52 岁免疫功能低下的男性患者,在 SARS-CoV-2 感染后发生假巴西诺卡氏菌性肺炎。我们还总结了诺卡氏菌病和 SARS-CoV-2 合并感染的文献。无论是否存在其他合并感染,诺卡氏菌属感染仍应作为免疫功能低下宿主肺炎的鉴别诊断之一。磺胺类药物/碳青霉烯类联合用药作为经验性治疗诺卡氏菌病;需要进行菌种鉴定和药敏试验,为每位患者选择最佳治疗方案。